CD4 and neoplasm: ERC1671, combining whole inactivated tumor cells and tumor cell lysates, showed significant effects in rGBM patients, particularly those naive to or resistant to BEV, with an average OS of 328 days and a correlation between peripheral blood CD4+ T lymphocyte counts and survival (57).